Should You Accumulate AN2 Therapeutics Inc (ANTX) Stock Friday Morning?

AN2 Therapeutics Inc (ANTX) is lower by Friday morning, with the stock falling -2.42% in pre-market trading to 3.23. ANTX's short-term technical score of 9 indicates that the stock has traded less bullishly over the last month than 91% of stocks on the market. In the Biotechnology industry, which ranks 103 out of 146 industries, AN2 Therapeutics Inc ranks higher than 15% of stocks. AN2 Therapeutics Inc has fallen 82.37% over the past month, closing at $19.50 on January 26. During this period of time, the stock fell as low as $3.33 and as high as $21.40. ANTX has an average analyst recommendation of Buy. The company has an average price target of $7.00.

ANTX has an Overall Score of 41. Find out what this means to you and get the rest of the rankings on ANTX!

See Full ANTX Report

AN2 Therapeutics Inc has a Long-Term Technical rank of 16. This means that trading over the last 200 trading days has placed the company in the lower half of stocks with 84% of the market scoring higher. In the Biotechnology industry which is number 70 by this metric, ANTX ranks better than 70% of stocks.

Important Dates for Investors in ANTX:

-AN2 Therapeutics Inc is set to release earnings on 2024-04-03. Over the last 12 months, the company has reported EPS of $-2.84. -We do not have a set dividend date for AN2 Therapeutics Inc at this time. Click Here To Get The Full Report on AN2 Therapeutics Inc (ANTX)